Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Diluted Average) (2021 - 2023)

Gyre Therapeutics (GYRE) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $37.8 million as the latest value for Q3 2023.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 20.2% to $37.8 million in Q3 2023 year-over-year; TTM through Sep 2023 was $37.8 million, a 20.2% increase, with the full-year FY2022 number at $31.5 million, up 2.95% from a year prior.
  • Shares Outstanding (Diluted Average) was $37.8 million for Q3 2023 at Gyre Therapeutics, roughly flat from $37.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $38.0 million in Q1 2023 to a low of $29.9 million in Q2 2021.
  • A 3-year average of $33.0 million and a median of $31.5 million in 2022 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 2.95% in 2022, then increased 20.75% in 2023.
  • Gyre Therapeutics' Shares Outstanding (Diluted Average) stood at $30.6 million in 2021, then rose by 2.95% to $31.5 million in 2022, then increased by 19.97% to $37.8 million in 2023.
  • Per Business Quant, the three most recent readings for GYRE's Shares Outstanding (Diluted Average) are $37.8 million (Q3 2023), $37.8 million (Q2 2023), and $38.0 million (Q1 2023).